Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cephalon
The objective of this study is to determine the tolerability and safety of OraVescent fentanyl when used long term to relieve breakthrough pain in opioid tolerant cancer patients.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18-80 years of age
Average of 1-4 breakthrough pain episodes per day
Opioid tolerant
Histologically documented diagnosis of a malignant solid tumor or hematological malignancy
You may not be if
Primary breakthrough pain is not related to cancer in any way
Opioid or fentanyl intolerance
Chronic obstructive pulmonary disease (COPD) or heart disease
Sleep apnea or active brain metastases with increased cranial pressure
Clareo Health | OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
